Significance of true-positive and false-positive pretransplantation lymphocytotoxic Crossmatch in primary liver allograft outcomes

Transplantation

Volumn 95, Issue 11, 2013, Pages 1410-1417

  Shin, Milljae ^a   Moon, Hyung Hwan ^a   Kim, Jong Man ^a   Park, Jae Berm ^a   Kwon, Choon Hyuck David ^a   Kim, Sung Joo ^a   Lee, Suk Koo ^a   Joh, Jae Won ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Autoantibody; Graft outcome; Liver transplantation; Lymphocytotoxic crossmatch.

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN M ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; BLOOD GROUP TYPING; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIGESTIVE SYSTEM CANCER; FALSE POSITIVE RESULT; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART DISEASE; HEPATIC ARTERY THROMBOSIS; HEPATITIS B; HUMAN; INFANT; KIDNEY CANCER; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG CANCER; LYMPHOCYTOTOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OVERALL SURVIVAL; PANCREAS CANCER; PORTAL VEIN THROMBOSIS; POSTOPERATIVE PERIOD; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PREOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY FAILURE; SCHOOL CHILD; SEPSIS; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; BLOOD GROUPING AND CROSSMATCHING; CHILD; CHILD, PRESCHOOL; FALSE POSITIVE REACTIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN M; INCIDENCE; INFANT; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; RETROSPECTIVE STUDIES; TRANSAMINASES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879869001     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31828d155a     Document Type: Article

References (46)

1. Opelz G, Dohler B, Susal C. Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study. Hum Immunol 2009; 70: 627
2. Takaya S, Duquesnoy R, Iwaki Y, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23: 396
3. Neumann UP, Lang M, Moldenhauer A, et al. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. Transplantation 2001; 71: 1163
4. Bishara A, Brautbar C, Eid A, et al. Is presensitization relevant to liver transplantation outcome? Hum Immunol 2002; 63: 742
5. Manez R, Kelly RH, Kobayashi M, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology 1995; 21: 1345
6. Muro M, Marin L, Miras M, et al. Liver recipients harbouring antidonor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre. Transpl Immunol 2005; 14: 91
7. Nakamura K, Murase N, Becich MJ, et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993; 142: 1383
8. Wang-Rodriguez J, Rearden A. Effect of crossmatching on outcome in organ transplantation. Crit Rev Clin Lab Sci 1995; 32: 345
9. Takaya S, Bronsther O, Iwaki Y, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53: 400
10. Batts KP,Moore SB, Perkins JD, et al. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988; 45: 376
11. Takaya S, Jain A, Yagihashi A, et al. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999; 31: 2028
12. Charco R, Balsells J, Murio E, et al. Adverse impact of high panelreactive antibody (PRA) and positive cytotoxic crossmatch in liver transplantation. Transpl Int 1994; 7: S94
13. Charco R, Vargas V, Balsells J, et al. Influence of anti-HLA antibodies and positive T-lymphocytotoxic crossmatch on survival and graft rejection in human liver transplantation. J Hepatol 1996; 24: 452
14. Gugenheim J, Baldini E, Pommier Bernard G, et al. Prognostic value of crossmatch in liver transplantation. Transplant Proc 1999; 31: 552
15. Bathgate AJ, McColl M, Garden OJ, et al. The effect of a positive Tlymphocytotoxic crossmatch on hepatic allograft survival and rejection. Liver Transpl Surg 1998; 4: 280
16. Demetris AJ, Nakamura K, Yagihashi A, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671
17. Ogura K, Terasaki PI, Koyama H, et al. High one-month liver graft failure rates in flow cytometry crossmatch-positive recipients. Clin Transplant 1994; 8: 111
18. Doyle HR, Marino IR, Morelli F, et al. Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch. Ann Surg 1996; 224: 168
19. Hathaway M, Gunson BK, Keogh AC, et al. A positive crossmatch in liver transplantationYno effect or inappropriate analysis? A prospective study. Transplantation 1997; 64: 54
20. Donaldson PT, Thomson LJ, Heads A, et al. IgG donor-specific crossmatches are not associated with graft rejection or poor graft survival after liver transplantation. An assessment by cytotoxicity and flow cytometry. Transplantation 1995; 60: 1016
21. Saito T, Mizuta K, Hishikawa S, et al. Lymphocytotoxic crossmatch in pediatric living donor liver transplantation. Pediatr Transplant 2009; 13: 194
22. Suehiro T, Shimada M, Kishikawa K, et al. Influence of HLA compatibility and lymphocyte cross-matching on acute cellular rejection following living donor adult liver transplantation. Liver Int 2005; 25: 1182
23. Sugawara Y, Tamura S, Kaneko J, et al. Positive lymphocytotoxic crossmatch does not adversely affect survival in living donor liver transplantation. Dig Surg 2009; 26: 482
24. Ashihara E, Tsuji H, Sakashita H, et al. Antidonor antibody in patients receiving ABO-identical and HLA-mismatched living donor liver transplants: effect on survival. Transplantation 2007; 83: 506
25. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554
26. Takakura K, Kiuchi T, Kasahara M, et al. Clinical implications of flow cytometry crossmatch with T or B cells in living donor liver transplantation. Clin Transplant 2001; 15: 309
27. Goh A, Scalamogna M, De Feo T, et al. Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl 2010; 16: 308
28. Al-Sibae MR, Koffron AJ, Raofi V. Does a positive pretransplant crossmatch affect long-term outcome in liver transplantation? Transplantation 2011; 91: 261
29. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012; 12: 171
30. Ruiz R, Tomiyama K, Campsen J, et al. Implications of a positive crossmatch in liver transplantation: a 20-year review. Liver Transpl 2012; 18: 455
31. Nakamura K, Yagihashi A, Iwaki Y, et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc 1991; 23: 3021
32. Kerman RH, Susskind B, Buyse I, et al. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 1999; 68: 1855
33. Susal C, Dohler B, Opelz G. Graft-protective role of high pretransplantation IgA-anti-Fab autoantibodies: confirmatory evidenceobtained in more than 4000 kidney transplants. The Collaborative Transplant Study. Transplantation 2000; 69: 1337
34. Anderson LA, Gadalla S, Morton LM, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009; 125: 398
35. Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009; 100: 822
36. Arslan C, Kilickap S, Yalcin S. Gastric cancer after cadaveric liver transplantation in a patient with autoimmune hepatitis: a case report and review of the literature. Turk J Gastroenterol 2011; 22: 73
37. Kristinsson SY, Bjorkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011; 29: 2897
38. van de Schans SA, van Spronsen DJ, Hooijkaas H, et al. Excess of autoimmune and chronic inflammatory disorders in patients with lymphoma compared with all cancer patients: a cancer registrybased analysis in the south of the Netherlands. Autoimmun Rev 2011; 10: 228
39. Zintzaras E, Voulgarelis M,Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337
40. Shpilberg O, Wilson J, Whiteside TL, et al. Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. Leuk Lymphoma 1999; 36: 109
41. Zimmermann T, Hoppe-Lotichius M, Tripkovic V, et al. Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for post-transplant lymphoproliferative disease (PTLD). Eur J Intern Med 2010; 21: 208
42. Reines BP. Hypothesis. Bystanders or bad seeds? Many autoimmunetarget cells may be transforming to cancer and signalling ''danger'' to the immune system. Autoimmunity 2001; 33: 121
43. Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008; 222: 328
44. Zhang JY, Zhu W, Imai H, et al. De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol 2001; 125: 3
45. Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res 2012; 32: 1119
46. Ngu JH, Gearry RB, Frampton CM, et al. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012; 55: 522.